High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy

International Journal of Urology ◽

10.1111/iju.12856 ◽

2015 ◽

Vol 22 (9) ◽

pp. 834-834

Author(s):

Robert J van Soest

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Editorial Comment ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Docetaxel Chemotherapy

High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy

International Journal of Urology ◽

10.1111/iju.12839 ◽

2015 ◽

Vol 22 (9) ◽

pp. 827-833 ◽

Cited By ~ 16

Author(s):

Akihisa Yao ◽

Takehiro Sejima ◽

Hideto Iwamoto ◽

Toshihiko Masago ◽

Shuichi Morizane ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Poor Clinical Outcome ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer

PLoS ONE ◽

10.1371/journal.pone.0158952 ◽

2016 ◽

Vol 11 (7) ◽

pp. e0158952 ◽

Cited By ~ 24

Author(s):

Vincenza Conteduca ◽

Simon J. Crabb ◽

Robert J. Jones ◽

Orazio Caffo ◽

Tony Elliott ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Outcome ◽

Lymphocyte Ratio ◽

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

ESMO Open ◽

10.1016/j.esmoop.2021.100241 ◽

2021 ◽

Vol 6 (5) ◽

pp. 100241

Author(s):

R. de Wit ◽

C. Wülfing ◽

D. Castellano ◽

G. Kramer ◽

J.-C. Eymard ◽

...

Keyword(s):

Prostate Cancer ◽

Prognostic Biomarker ◽

Predictive And Prognostic Biomarker

Lymphocyte Ratio ◽

Castration Resistant ◽

Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

Prostate Cancer and Prostatic Diseases ◽

10.1038/s41391-020-0209-3 ◽

2020 ◽

Vol 23 (2) ◽

pp. 220-231 ◽

Cited By ~ 9

Author(s):

Yupeng Guan ◽

Haiyun Xiong ◽

Yupeng Feng ◽

Guolong Liao ◽

Tongyu Tong ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Meta Analysis ◽

Platelet To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

2578 Neutrophil-to-lymphocyte ratio (NLR) in relation to outcome of castration-resistant prostate cancer (CRPC) patients treated with corticosteroids (CS)

European Journal of Cancer ◽

10.1016/s0959-8049(16)31397-1 ◽

2015 ◽

Vol 51 ◽

pp. S504

Author(s):

N. Mehra ◽

D. Lorente ◽

A. Jayaram ◽

D. Bianchini ◽

Z. Zafeiriou ◽

...

Keyword(s):

Prostate Cancer ◽

Lymphocyte Ratio ◽

Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio

World Journal of Urology ◽

10.1007/s00345-019-02658-1 ◽

2019 ◽

Vol 37 (11) ◽

pp. 2375-2384 ◽

Cited By ~ 2

Author(s):

Kyo Chul Koo ◽

Jong Soo Lee ◽

Jee Soo Ha ◽

Kyung Suk Han ◽

Kwang Suk Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Targeted Agents ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Optimal Sequencing ◽

Sequencing Strategy

Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: Utilization of neutrophil-to-lymphocyte ratio

European Urology Supplements ◽

10.1016/s1569-9056(18)31451-9 ◽

2018 ◽

Vol 17 (2) ◽

pp. e886-e887

Author(s):

K.C. Koo ◽

J.S. Lee ◽

S.K. Kang ◽

J.W. Kim ◽

K.S. Lee ◽

...

Keyword(s):

Prostate Cancer ◽

Androgen Receptor ◽

Targeted Agents ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Optimal Sequencing ◽

Sequencing Strategy

Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2017.05.012 ◽

2017 ◽

Vol 15 (6) ◽

pp. 678-684.e1 ◽

Cited By ~ 10

Author(s):

Niven Mehra ◽

Adam Sharp ◽

David Lorente ◽

David Dolling ◽

Semini Sumanasuriya ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Lymphocyte Ratio ◽

Castration Resistant ◽

Oral Corticosteroids

Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and its kinetics as prognostic markers for patients with metastatic castration resistant prostate cancer treated with Enzalutamide

10.26226/morressier.5f4d10acb0f0f3411b830968 ◽

2020 ◽

Author(s):

Rita Sofia Vitorino da Silva Paiva

Keyword(s):

Prostate Cancer ◽

Prognostic Markers ◽

Platelet To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽